Personalised breast cancer prevention is a modern approach based on genetic risk testing. It addresses the key issue that 20% of breast cancer cases are diagnosed in women under 50, who are typically not screened. By combining polygenic risk score (PRS) technology into breast cancer prevention, it is possible to identify women who require earlier screening.
AnteBC is a genetic test that assesses a woman’s risk of developing breast cancer using polygenic risk score (PRS) technology. It is a clinical tool that estimates the breast cancer risk level of an individual for precise and efficient prevention and screening. AnteBC test is recommended for women between the ages of 30 and 75.
The integration of PRS genetic tests into clinical practice represents a new standard of care in personalised medicine, supported by extensive research and clinical evidence from numerous studies.
Read more about how to implement personalised breast cancer prevention below.
